The Institute for Clinical and Industrial Research 's ( CSI ) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen 's Spinzara therapy if priced at $ 2 m . Dave Lennon , president of Novartis ' But it won’t be the last time the influential agency gets out ahead of high-priced treatments, Lennon predicted. AveXis unit , said CSI 's report is positive for cell - based therapies and gene - therapy assessments but highlighted the need for bio - pharmaceutical companies to consider developing alternative payment models for such treatments . Novartis already offers an outcome - based payment model for its blood cancer treatment Kymriah and ultimately , Lennon said , the onus will be on treatment developers to prove the value of their therapies .
The Institute for Clinical and Industrial Research 's ( CSI ) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen 's Spinzara therapy if priced at $ 2 m . Dave Lennon , president of Novartis ' AveXis unit , said CSI 's report is positive for cell - based therapies and gene - therapy assessments but highlighted the need for bio - pharmaceutical companies to consider developing alternative payment models for such treatments . Novartis already offers an outcome - based payment model for its blood cancer treatment Kymriah and ultimately , Lennon said , the onus will be on treatment developers to prove the value of their therapies .